Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Human+ vs Medro

Human+
Graded #334

Lower grade

vs+3.8000000000000043
Medro
Graded #255

Higher grade

The verdict

Medro takes it — 63.6/100 to 59.8/100.

Medro grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Medro (Medro Health Technologies, Inc.) is a telehealth brand whose GLP-1 program offers compounded semaglutide and tirzepatide, plus brand-name GLP-1s when eligible, via a partner medical group and…

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueMedro +5
45
50
Dose & formulationMedro +37
40
77
Clinical oversightHuman+ +12
83
71
Labs & monitoringHuman+ +14
66
52
FulfillmentMedro +2
90
92
Contract termsHuman+ +8
41
33
Human+ · left barMedro · right bar

The numbers

MetricHuman+Medro
WeighScore59.8/10063.6/100
GradeCC
Scorecard rank#334#255
SemaglutideNot disclosed$199/mo (compounded)
TirzepatideNot disclosed$299/mo (compounded)
CoverageAll 50 statesAll 50 states
Brand-name accessCompounded onlyYes
Oral / sublingualInjection onlyInjection only
Human+

Graded #334 · C

Strengths

  • Cost-transparent model: a flat monthly membership with prescriptions billed at pharmacy-wholesale cost instead of marked up
  • Available via telehealth in all 50 states
  • Filled by US 503A compounding pharmacies and reviewed by board-certified US-licensed clinicians
  • Fast, fully online 5-minute intake with provider review often within hours; discreet plain packaging
  • Covers weight loss plus hair, sexual wellness, mental health, and labs under one membership

Where it loses points

  • Specific GLP-1 medications and pricing are not published — you only see them after starting the intake
  • Compounded medications are not FDA-approved — not brand Wegovy, Ozempic, Zepbound, or Mounjaro
  • LegitScript certification is shown only as a self-hosted badge; no verifiable LegitScript seal was found
  • Minimal public-facing site and a flat membership fee on top of the medication cost
Medro

Graded #255 · C

Strengths

  • Covers both compounded semaglutide and tirzepatide and can prescribe brand-name GLP-1s when clinically appropriate.
  • LegitScript-certified (seal #50716646), available in all 50 states, with tiered pricing shown before checkout.
  • No membership fee and free expedited shipping on all orders; online intake with no appointment required in many cases.
  • Prices drop with longer commitments (semaglutide to $149/mo, tirzepatide to $224/mo on a 12-month plan).

Where it loses points

  • Does not name its compounding pharmacy or its clinical partner medical group, so the fulfillment chain is not verifiable.
  • Pricing is described as illustrative and may change by dose, pharmacy availability, and eligibility — final cost shows only at checkout.
  • Very new brand (2026, trademark pending) spanning many verticals, with a short track record in GLP-1 care.
  • Compounded medications are not FDA-approved or therapeutically equivalent to Ozempic, Wegovy, Mounjaro, or Zepbound.

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard